258 related articles for article (PubMed ID: 26010760)
1. Host cell proteins in biotechnology-derived products: A risk assessment framework.
de Zafra CL; Quarmby V; Francissen K; Vanderlaan M; Zhu-Shimoni J
Biotechnol Bioeng; 2015 Nov; 112(11):2284-91. PubMed ID: 26010760
[TBL] [Abstract][Full Text] [Related]
2. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
[TBL] [Abstract][Full Text] [Related]
3. A novel 'pipeline' system for downstream preparation of therapeutic monoclonal antibodies.
Wang F; Yan X; Song L; Wang P; Lu D; Feng J; Yang D; Yan X
Biotechnol Lett; 2013 Sep; 35(9):1411-8. PubMed ID: 23881311
[TBL] [Abstract][Full Text] [Related]
4. Rational and systematic protein purification process development: the next generation.
Nfor BK; Verhaert PD; van der Wielen LA; Hubbuch J; Ottens M
Trends Biotechnol; 2009 Dec; 27(12):673-9. PubMed ID: 19815300
[TBL] [Abstract][Full Text] [Related]
5. Expression of difficult-to-remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessing.
Valente KN; Lenhoff AM; Lee KH
Biotechnol Bioeng; 2015 Jun; 112(6):1232-42. PubMed ID: 25502542
[TBL] [Abstract][Full Text] [Related]
6. Aggregates in monoclonal antibody manufacturing processes.
Vázquez-Rey M; Lang DA
Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
[TBL] [Abstract][Full Text] [Related]
7. Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation.
Hamrang Z; Rattray NJ; Pluen A
Trends Biotechnol; 2013 Aug; 31(8):448-58. PubMed ID: 23769716
[TBL] [Abstract][Full Text] [Related]
8. Precipitation as an Enabling Technology for the Intensification of Biopharmaceutical Manufacture.
Martinez M; Spitali M; Norrant EL; Bracewell DG
Trends Biotechnol; 2019 Mar; 37(3):237-241. PubMed ID: 30316558
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometry to describe product and contaminant adsorption properties for bioprocess development.
Berrill A; Ho SV; Bracewell DG
Biotechnol Bioeng; 2011 Aug; 108(8):1862-71. PubMed ID: 21351073
[TBL] [Abstract][Full Text] [Related]
10. Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives.
Baeshen MN; Al-Hejin AM; Bora RS; Ahmed MM; Ramadan HA; Saini KS; Baeshen NA; Redwan EM
J Microbiol Biotechnol; 2015 Jul; 25(7):953-62. PubMed ID: 25737124
[TBL] [Abstract][Full Text] [Related]
11. Mixing monoclonal antibody formulations using bottom-mounted mixers: impact of mechanism and design on drug product quality.
Gikanga B; Chen Y; Stauch OB; Maa YF
PDA J Pharm Sci Technol; 2015; 69(2):284-96. PubMed ID: 25868994
[TBL] [Abstract][Full Text] [Related]
12. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics.
Adamson SR
Dev Biol Stand; 1998; 93():89-96. PubMed ID: 9737383
[TBL] [Abstract][Full Text] [Related]
13. Manufacturing of biodrugs: need for harmonization in regulatory standards.
Sahoo N; Choudhury K; Manchikanti P
BioDrugs; 2009; 23(4):217-29. PubMed ID: 19697964
[TBL] [Abstract][Full Text] [Related]
14. Viruses and assuring viral safety.
Robertson JS
Dev Biol (Basel); 2003; 113():73-7. PubMed ID: 14620855
[No Abstract] [Full Text] [Related]
15. Advances in product release strategies and impact on bioprocess design.
Balasundaram B; Harrison S; Bracewell DG
Trends Biotechnol; 2009 Aug; 27(8):477-85. PubMed ID: 19573944
[TBL] [Abstract][Full Text] [Related]
16. Automated disposable small scale reactor for high throughput bioprocess development: a proof of concept study.
Bareither R; Bargh N; Oakeshott R; Watts K; Pollard D
Biotechnol Bioeng; 2013 Dec; 110(12):3126-38. PubMed ID: 23775295
[TBL] [Abstract][Full Text] [Related]
17. The Current Scientific and Regulatory Landscape in Advancing Integrated Continuous Biopharmaceutical Manufacturing.
Fisher AC; Kamga MH; Agarabi C; Brorson K; Lee SL; Yoon S
Trends Biotechnol; 2019 Mar; 37(3):253-267. PubMed ID: 30241924
[TBL] [Abstract][Full Text] [Related]
18. Clarification technologies for monoclonal antibody manufacturing processes: Current state and future perspectives.
Singh N; Arunkumar A; Chollangi S; Tan ZG; Borys M; Li ZJ
Biotechnol Bioeng; 2016 Apr; 113(4):698-716. PubMed ID: 26302443
[TBL] [Abstract][Full Text] [Related]
19. Biopharmaceuticals derived from genetically modified plants.
Goldstein DA; Thomas JA
QJM; 2004 Nov; 97(11):705-16. PubMed ID: 15496527
[TBL] [Abstract][Full Text] [Related]
20. Safety risk management for low molecular weight process-related impurities in monoclonal antibody therapeutics: Categorization, risk assessment, testing strategy, and process development with leveraging clearance potential.
Luo H; Li Y; Robbins D; Wang SC; Xi G; Cox M; Nicholson SM; Wei C; Pabst TM; Wang WK
Biotechnol Prog; 2021 May; 37(3):e3119. PubMed ID: 33373106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
